3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Sunitinib
64
Nivolumab
42
pembrolizumab
36
Bevacizumab
32
Everolimus
31
Sorafenib
25
pazopanib
23
Axitinib
23
cabozantinib
14
aldesleukin
13
Ipilimumab
13
temsirolimus
11
Interferon alpha-2
11
Cyclophosphamide
10
avelumab
9
Magnetic Resonance Spectroscopy
9
Interleukin-2
9
lenvatinib
8
atezolizumab
8
Radiosurgery
8
Gemcitabine
8
Immunoglobulin G
7
Erlotinib Hydrochloride
7
Disulfides
6
fludarabine phosphate
5
Radiotherapy
5
Fluorodeoxyglucose F18
5
peginterferon alfa-2b
4
Vorinostat
4
Tyrosine Kinase Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Renal Cell
×
pertuzumab
×
Clear all
No trials found.